News
21 December 2008: O.D.260 Inc files the "Method of Adenoviral Vector Synthesis" application to the WIPO.
28 October 2008: O.D.260 Inc files a patent application entitled "Method of Adenoviral Vector Synthesis" to the USPTO.
26 October 2008: O.D.260 Inc files the "Promoter Detection and Analysis" application to the WIPO.
27 October 2007: O.D.260 Inc files a patent application entitled "Promoter Detection and Analysis" to the USPTO.
1 February 2007:Recent O.D.260 acquisitions have increased our service production capacity by over 40%. This new capacity will allow us to maintain our very competitive pricing and our quick turn-around time for our increasing number of customers...
1 September 2006: O.D.260 is selected to participate in this year’s NIH SBIR Commercialization Assistance Program (NIH-CAP).
According to the NIH: "The NIH-CAP is designed to help some of the nation’s most promising life science small companies develop their commercial businesses and transition their SBIR-developed products into the marketplace."
1 June 2006: O.D.260 Inc. launches new website which includes many new and exciting products and services.
7 September 2005: O.D.260 Inc. president Xavier Danthinne presents to the Idaho Legislative Biotechnology Task Force. Biotechnology and research leaders throughout Idaho gather at the Capital. Their goal: present their views of research, present and future, in Idaho.
8 August 2005: O.D.260 Inc. makes the front page of Idaho Business Review. Read the full article "Getting the gene out of the bottle" (pdf).
8 June 2005: O.D.260 Inc. presents at the 2nd Annual Science and Technology Industry Forum in Boise Idaho.
1 March 2005: O.D.260 Inc. is awarded an SBIR Phase 1 grant from the National Institute of Health. This award will fund work to develop novel promoter analysis technologies.
15 September 2004: O.D.260 Inc. is awarded an SBIR Phase 2 grant from the National Institute of Health. This two year award will fund work on gutless Adenovirus technologies.
1 May 2001: O.D.260 Inc. is awarded an SBIR Phase 1 grant from the National Institute of Health. This nine-month year award will fund work on gutless Adenovirus technologies.